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A Role of the Ubiquitin–Proteasome System in Neuropathic Pain
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Neuropathic pain (characterized by hyperalgesia and allodynia
to mechanical and thermal stimuli) causes cellular changes in
spinal dorsal horn neurons, some of which parallel those in
synaptic plasticity associated with learning. Ubiquitin
C-terminal hydrolase (UCH) appears to play a key role in long-
term facilitation in Aplysia. The cooperation of UCH with the
proteolytic enzyme complex known as the proteasome is re-
quired for the degradation of a number of signaling molecules
within the cell that may remove normal restraints on synaptic
plasticity. We have used electrophysiology, in situ hybridization
histochemistry, semiquantitative RT-PCR, Western blotting, and
in vivo behavioral reflex analysis to investigate the ubiquitin–
proteasome system in a model of neuropathic pain. In neuro-
pathic animals, ionophoretic application of selective protea-
some inhibitors attenuated dorsal horn neuron firing evoked by
normally innocuous brush or cold stimuli and by noxious mus-
tard oil stimuli. In control animals, only mustard oil-evoked
responses were inhibited. Intrathecal administration of protea-
some inhibitors attenuated hyperalgesia and allodynia in neu-
ropathic rats. Expression of UCH-L1 (a rat homolog of Aplysia
neuronal UCH and of the human UCH-L1, also known as PGP
9.5) and its mRNA were selectively increased within the ipsilat-
eral dorsal horn of neuropathic rats, supporting the idea of a
role for the ubiquitin–proteasome system in nociceptive pro-
cessing. Proteasome inhibitors selectively attenuate allodynic
and hyperalgesic responses in neuropathic pain, with some
reduction in normal nociceptive, but not non-nociceptive re-
sponses, and potentially represent a novel therapeutic strategy
for neuropathic pain.
Key words: neuropathic pain; spinal cord; proteasome; ubiq-
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After damage to the distal parts of primary afferent neurons that
transmit nociceptive information, their abnormal and repetitive
firing is known to induce a state of neuronal hyperexcitability
within the spinal dorsal horn, referred to as “central sensitiza-
tion.” A characteristic consequence of this is the development of
accentuated pain-related behaviors, reflecting hyperalgesia and
allodynia in response to thermal and mechanical stimulation. In
animal models of neuropathic pain, these are associated with
various neurochemical and neuroanatomical changes occurring
within the nociceptive pathway itself (Ho¨kfelt et al., 1994; Woolf
et al., 1995; Chung et al., 1996; Cameron et al., 1997).
A number of the changes associated with central sensitization
in response to sustained nociceptive activation are similar to
those observed in animal models of synaptic plasticity, such as
long-term potentiation (LTP) in the mammalian hippocampus.
Both LTP and central sensitization trigger activity-dependent
changes in neuronal excitability via mechanisms including the
post-translational modification of membrane-bound proteins such
as the NMDA receptor. Downstream targets common to both
processes may include Ca2/calmodulin-dependent kinases, pro-
tein kinase C (PKC), protein kinase A (PKA), and nitric oxide
synthase (Bliss and Collingridge, 1993; Mayer et al., 1999). A
partially analogous process of long-term facilitation (LTF) of
synaptic responses occurs in Aplysia sensory pathways, where a
number of the molecular changes underlying LTF are evoked in
common by sensory neuron injury (Walters and Ambron, 1995).
In the LTF model, sustained sensory neuron activation induces
the activation of PKA with the dissociation of PKA regulatory
subunits and the translocation of the constitutively active free
catalytic subunits to the cell nucleus (Chain et al., 1999). The
ubiquitin–proteasome system appears to play a vital role in the
regulation of PKA activity by degrading the regulatory subunits
of PKA, which normally maintain PKA in an inactive state.
Stimulus-induced degradation of PKA regulatory subunits is thus
thought to lead to persistent activation of the kinase and main-
tenance of the synapse in a facilitated state (Greenberg et al.,
1987; Chain et al., 1999).
The ubiquitin–proteasome system is a major non-lysosomal
proteolytic pathway that degrades diverse cellular proteins, in-
cluding a number of proteins with important roles in the regula-
tion of cell growth or function (Coux et al., 1996; Rolfe et al.,
1997; Hershko and Ciechanover, 1998). For example, protein
degradation by this pathway is important for the control of PKA
activity (Hegde et al., 1993). The functional activity of the pro-
teasome is enhanced by the UCH family of isopeptidases, which
appear to play a crucial role in maintaining activity by preventing
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accumulation of inhibitory polyubiquitin chains (Wilkinson,
1997). The present study explores the contribution made by the
ubiquitin–proteasome system to the central sensitization, hyper-
algesia, and allodynia that characterize intractable neuropathic
pain.
MATERIALS AND METHODS
Chronic constriction injury to the sciatic nerve
All experiments were performed in accordance with the United King-
dom Animals (Scientific Procedures) Act, 1986. Adult male Wistar rats
(200–350 gm, Charles River, Kent, UK) were anesthetized with sodium
pentobarbital (Sagatal 0.06 ml/100 gm, i.p.; Rhoˆne Merieux, Essex, UK)
and supplemented with halothane/O2 (Zeneca, Cheshire, UK). Under
aseptic conditions, the right sciatic nerve was exposed proximal to the
trifurcation, at a mid-thigh level, and four chromic cat gut ligatures (4:0;
Ethicon, Edinburgh, UK) were tied to loosely constrict the nerve [chronic
constriction injury (CCI)], as viewed under 40 magnification (Bennett
and Xie, 1988). The overlying muscle and skin were closed with sutures
(4:0; Ethicon), and the animals were allowed to recover for 72 hr before
reflex testing recommenced. Sham-operated animals underwent the same
surgical procedure, but no ligatures were placed around the nerve.
Behavioral tests
Behavioral testing was performed before surgery to establish a baseline
for comparison with post-surgical values. Inspections were made regu-
larly for signs of autotomy, which was rarely observed. CCI animals were
always assessed for the presence of thermal hyperalgesia, cold, and
mechanical allodynia before being used for further study in other tests.
Only in occasional cases did reflex sensitization fail to develop, and in
those examples technical factors appeared to be responsible. The follow-
ing behavioral reflex tests were performed as described in detail previ-
ously (Blackburn-Munro et al., 1999; Dickinson et al., 1999). Thermal
hyperalgesia was monitored using noxious radiant heat (30–55°C; Har-
greaves’ thermal device, Linton Instruments, Diss, UK) applied to the
mid-plantar glabrous surface of the hindpaw. The withdrawal response
latency was characterized as a brief paw flick recorded to the nearest 0.1
sec; a standard cutoff latency of 20 sec prevented tissue damage.
Mechanical allodynia was measured as the threshold for paw with-
drawal in response to graded mechanical stimuli applied to the mid-
plantar glabrous surface of the hindpaw using calibrated von Frey fila-
ments (Stoelting, Wood Dale, IL). Threshold was defined as the pressure
(force per unit area) that caused foot withdrawal five times in every 10
applications, repeated at 1–2 sec intervals. The pressure applied to the
hindlimb by the von Frey filaments is calibrated as force (milliNewtons)
divided by the area over which it is applied (millimeters squared).
To detect the presence of cold allodynia, rats were placed in a perspex
box with an elevated aluminum floor covered with iced water, sufficient to
immerse both glabrous and hairy skin of the hindpaw (3–4°C) (Bennett
and Xie, 1988). Once placed in the box, rats were allowed 10 sec to
acclimatize. The number of seconds the animal raised its hindpaw above
the water over a 20 sec period was recorded. This was repeated four times
at 10 min intervals to establish a mean suspended paw elevation time
(SPET) for each rat. Animals determined as being at the peak of
neuropathy, 12–14 d after CCI surgery, were then used in the experi-
ments described below.
Intrathecal drug treatment
The effects of intrathecal administration of the selective proteasome
inhibitors MG-132 (Rock et al., 1994) and epoxomicin (Sin et al., 1999)
on behavioral reflex responses were examined. Before determining the
effects of these inhibitors, baseline measurements were recorded in rats
[normal (i.e., naive), n  8; neuropathic, n  26] both before and at the
peak of neuropathy. A minimum of four measurements were made for
each test session, for each sensory test. Rats were anesthetized briefly
with halothane/O2 and injected intrathecally at the L5 level of the spinal
cord with 5 nmol of MG-132 or 0.75 nmol of epoxomicin in saline with
0.5% dimethylformamide (50 l), using a 25 gauge needle microsyringe.
Injection of vehicle had no discernable effect on behavioral reflexes. The
identity of the drug was concealed from the experimenter to eliminate
bias, and dye injections (Pontamine Sky Blue) were performed in sepa-
rate experiments to define the correct site of injection. Testing began 15
min after injection (a delay to allow for full recovery of reflex function
after anesthesia) and was performed at 5 min (thermal hyperalgesia and
mechanical allodynia) or 10 min intervals (cold allodynia). Testing con-
tinued until recovery to pre-injection values.
Single neuron electrophysiological recording experiments
After induction of anesthesia with halothane/O2, rats (normal, n  8;
sham, n  4; neuropathic, n  11) underwent jugular vein and tracheal
cannulations. Anesthesia was then maintained using intravenous
-chloralose (60 mg/kg) and urethane (1.2 mg/kg). Supplementary doses
of -chloralose were given as required. Core temperature was main-
tained at 37–38°C, and O2 (0.1 l /min) was passed over the end of the
cannula to enrich the inspired air. A laminectomy (segments L3–L6) was
performed, as described previously (Blackburn-Munro and Fleetwood-
Walker, 1997). Extracellular recordings were made from single, multi-
receptive neurons (laminas III–V), ipsilateral to the nerve injury in
neuropathic animals and bilaterally in unoperated, naı¨ve control rats via
the central barrel (4 M NaCl, pH 4.0–4.5) of a multibarreled glass
microelectrode (tip size 4–5 m). One side barrel contained 1 M NaCl,
pH 4.5, for automatic current balancing using a Neurophore BH2 Iono-
phoresis System (Medical Systems Corporation). The remaining barrels
contained drugs for ionophoretic application of drug: the selective pro-
teasome inhibitors lactacystin (Fenteany et al., 1995) and MG-132 (both
in 0.5% aqueous dimethylformamide, pH 4.5, at concentrations of 500
and 200 M, respectively; Biomol, Plymouth Meeting, PA). Drugs were
ejected using positive currents of 5–60 nA, and a retention current of
12 nA was applied to each side barrel when not in use to minimize drug
leakage. The resistance of the side barrels was monitored regularly, and
electrodes with resistance values in excess of 45 M were rejected.
The effects of the inhibitors were examined on evoked responses of
neurons to sensory stimulation in both naive and neuropathic animals.
Sustained activation of neurons was obtained by the following stimuli,
described in detail elsewhere (Dickinson et al., 1999): (1) a rotating
motorized innocuous brush for low threshold mechanical stimulation and
(2) an intense cold stimulus provided by a Peltier device [5°C for 10 sec,
from 32°C (ramp rate 5°C/sec), over a surface area of 1 cm 2; Medical
Instruments, Yale University, New Haven, CT]. The stimuli were re-
peated every 1–2 min to give reproducible peaks of activity. (3) Topical
application of the C-fiber-selective chemical algogen, mustard oil [allyl
isothiocyanate (Aldrich Chemical Company), 7.5% solution in paraffin
oil, applied up to seven times at 5 min intervals].
Drugs were ejected ionophoretically in a step-wise manner (usually in
increments of 10 nA, over a range of 5–60 nA) every 1–2 min, until clear
effects on the neuronal firing rate were observed; if none was observed by
60 nA after 2 min duration, the drug application was terminated. For the
majority of neurons, both drugs were tested on responses to all three
sensory stimuli.
Action potential discrimination enabled data to be digitized and down-
loaded onto a computer to give a record of cell firing rate measured as
action potentials per second. After subtraction of the “background”
activity, the firing rate after drug application was expressed as the
percentage change from control responses of the neuron before drug
application.
Determination of levels of mRNA for ubiquitin
C-terminal hydrolase-L1
mRNA analysis by RT-PCR. Relevant segments of spinal cord were
dissected into ipsilateral and contralateral sides and immersed in liquid
nitrogen. Total RNA was extracted using Trizol (Invitrogen, Paisley,
UK) according to the manufacturer’s guidelines. The cDNAs were ob-
tained using SuperScript II Moloney’s murine leukemia virus reverse
transcriptase (Invitrogen) according to the manufacturer’s protocol.
Briefly, 5 g DNase-treated total RNA was added to reverse transcrip-
tion buffer (50 mM Tris-Cl, pH 8.3, 75 mM KCl, 5 mM MgCl2) containing
17 U RNAsin (Invitrogen), 10 mM dNTPs, and 0.5 M poly(dT)12–18
primer. Semiquantitative PCR was performed for rat ubiquitin
C-terminal hydrolase-L1 (UCH-L1)/PGP 9.5 homolog (Wilkinson et al.,
1989; Kajimoto et al., 1992) and for the metabolic housekeeping enzyme,
glyceraldehyde-3-phosphodehydrogenase (GAPDH). An excess of UCH
amplification primers (forward: 5-GCT GCT GCT GTT TCC CCT
CAC; reverse: 5-AGA CCT TGG CGG CAT CCT G) (MWG Biotech)
(0.5 M final concentration), supplemented with 5 U Taq DNA polymer-
ase (Invitrogen), and 2 l of the first-strand reaction mix, were used for
each amplification. PCR cycling conditions were as follows: 1 cycle of 5
min at 94°C, and 22 cycles of 45 sec at 94°C, 30 sec at 56°C, 1 min at 72°C.
This resulted in a linear amplification of the 324 base pair (bp) UCH-L1
DNA fragment, as quantified by direct measurements of fluorescence of
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the amplified fragments using a digital imaging system (UVP) and
Scan-Analysis software (Biosoft). A second round of PCR was per-
formed in the presence of 3-NH2-linked GAPDH primers in an 8:2
molar ratio with standard GAPDH primers: forward, 5-GGC AGC CCA
GAA CAT CAT CC; reverse, 5-CAG CCC CAG CAT CAA AGG TG.
This produced levels of fluorescence comparable to the 324 bp UCH-L1
PCR fragment using PCR conditions identical to those above.
After coamplification of the target UCH-L1 and GAPDH sequences,
equal amounts of reaction products were analyzed by gel electrophoresis
in a 2% (w/v) agarose gel containing 0.5 g/ml ethidium bromide.
Relative levels of UCH-L1 mRNA expression were calculated by express-
ing relative levels of UCH-L1 mRNA fluorescence as a percentage of
GAPDH mRNA fluorescence.
In situ hybridization histochemistry. Neuropathic animals and age-
matched naı¨ve controls were deeply anesthetized with halothane/O2 (4%
for induction and maintenance), and a laminectomy (L3–L6) was per-
formed for spinal cord removal. Tissue was mounted on a cryostat chuck
(OCT Embedding Matrix, CellPath Ltd., Wales, UK) and snap frozen in
isopentane (BDH, Poole, UK) at 40 to 45°C. Frozen transverse
sections of spinal cord (10 m) were taken at 19°C in a cryostat and
thaw-mounted onto poly-lysine-coated microscope slides (BDH).
Two oligonucleotides (synthesized by Oswel DNA Service) comple-
mentary and specific to nucleotides 299–333 and 658–693 of rat UCH-L1
mRNA were used (Kajimoto et al., 1992). The oligonucleotides were 3
end-labeled with deoxyadenosine [ 35S]-triphosphate (specific activity
1250 Ci/mol; DuPont NEN) using terminal deoxynucleotidyl trans-
ferase (Promega). In situ hybridization histochemistry was performed
using methodology described previously (Blackburn-Munro and
Fleetwood-Walker, 1999). Controls used to demonstrate specificity of
the respective oligonucleotide consisted of (1) pretreating sections with
RNase A (1 mg/ml; Sigma, Poole, UK) for 1 hr before hybridization and
(2) coincubation of the 35S-labeled oligonucleotide in the hybridization
medium with a 100-fold excess of unlabeled oligonucleotide.
Image analysis
Cell counts. The number of cells positively hybridized for UCH-L1 within
lateral and midway between lateral and medial (“mediolateral”) locations
of laminas I–V was calculated at 40magnification (total grid area 175
175 m). Cells were considered to be positively labeled if the silver grains
showed a dense pattern around the nucleus and were fivefold denser than
a typical nonexpressing cell within the same field area or background
levels. The total number of positively hybridized cells was determined for
each spinal cord section (n  10 sections), and these values were used to
calculate the mean number of positively hybridized cells per unit area, in
the lumbar spinal segments L3–L6 (naı¨ve, n  4; neuropathic, n  4).
Silver grain counting. To assess any changes in the relative expression of
UCH-L1 mRNA after chronic constriction injury, the mean silver grain
density per positively labeled cell was measured using Image 1.44 soft-
ware (Improvision) with video input from a charge-coupled device
camera (Sony, Tokyo, Japan) mounted on a Zeiss Axioscope microscope
(40 magnification). For each section, counts were made both ipsilateral
and contralateral to the nerve injury in lateral and medial zones. A
minimum of five positively hybridized cells was counted in each region.
A pixel count was obtained, which was converted to silver grain number
via a predetermined calibration procedure. The mean number of silver
grains per cell was calculated for each section (n 10 sections). Then the
mean number of silver grains per cell could be calculated. In total, 500
positively hybridized cells were counted within one side of the spinal
dorsal horn for each animal.
Western blot analysis of the expression of ubiquitin C-terminal hydrolase.
Hemisected L3–L6 spinal cord samples (naive, n  4; neuropathic, n 
4; sham, n  4) were homogenized into standard Laemmli buffer and
denatured at 100°C for 5 min. Extracts were separated by electrophoresis
on precast 10% polyacrylamide gels (Bio-Rad, Hemel Hempstead, UK),
transferred to polyvinylidene difluoride membrane, and blocked over-
night at 4°C in 4% Marvel, 0.1% Tween 20. Blots were probed with
primary antibody to UCH-L1/PGP 9.5 (Affiniti; 1:5000) or GAPDH
(Chemicon; 1:750) and detected by peroxidase-linked secondary anti-
body enhanced chemiluminescence.
Ex vivo PK A activity assays. After lumbar laminectomy under anes-
thesia, rats, (naı¨ve, n  3; neuropathic, n  3) were treated by topical
application of agents to the dorsal surface of the spinal cord. Epoxomicin
(15 M), MG-132 (100 M),or vehicle (0.5% dimethylformamide in
saline) was applied in a volume of 500 l for 1 hr before rapid removal
of segments L3–L6 to cold buffer on ice. cAMP-evoked PKA enzymatic
activity and constitutive activity (thought to reflect PKA previously
activated in situ) were measured by the following procedure, a modifi-
cation of those of Roskoski (1983) and Corbin (1983). Hemisected spinal
cord samples were rapidly homogenized on ice in 20 mM Na HEPES, pH
7.5, with 5% glycerol, 0.25% BSA, 1 mM EGTA, 1 mM dithiothreitol, 1
mM 4-(2-aminoethyl) benzene sulfonyl fluoride (Alexis Corporation,
Nottingham, UK), 2 g/ml aprotinin, 10 g/ml leupeptin, 2 g/ml
pepstatin, 50 g/ml soybean trypsin inhibitor, 25 mM Na
-glycerophosphate, 1 mM Na orthovanadate, 1 mM NaF, 1 M calyculin
A, 1 M cypermethrin (Calbiochem, Nottingham, UK), and 500 M
isobutyl methylxanthine. All reagents were from Sigma unless indicated
otherwise. Aliquots of homogenate were incubated for 10 min at 30°C
(linear range of assay) with 100 M kemptide as substrate, 100 M ATP
(with [ 33P] -ATP to 0.2 Ci per tube; DuPont NEN, Dreiech, Germa-
ny), 10 mM MgCl2, and 10 M cAMP and/or 1 M PKI6–22 amide
(Calbiochem) as appropriate. Assays were terminated with cold TCA (to
10%), centrifugation, and spotting of the supernatant onto P81 phospho-
cellulose paper. Samples were washed extensively in 75 mM H3PO4 and
dried before scintillation counting. Positive controls were performed with
purified bovine heart PKA catalytic subunit, and each homogenate was
assayed in parallel for cAMP-evoked activity (in the absence or presence
of PKI6–22 amide), constitutive activity (in the absence or presence of
PKI6–22 amide), and zero time incubation blanks. Authentic (PKI6–22
amide-sensitive) PKA-activity was always 86–97% of the recorded activ-
ity for constitutive and cAMP-evoked conditions, and zero time blanks
were always 2% of total activity.
Subcellular distribution of specific [ 3H] phorbol dibutyrate binding sites.
After topical application of drugs and homogenization in the same
ice-cold medium as for PKA assays above, spinal cord (L3–L6) homog-
enates were assayed for membrane/cytosol content of specific [ 3H] phor-
bol dibutyrate binding sites as described previously (Johnson et al.,
1996). Briefly, after centrifugation at 12,000  g for 20 min, the mem-
brane pellet was resuspended in 50 mM Tris HCl, pH 7.4, with 4 mg/ml
fatty acid-free BSA (Tris BSA), and aliquots were incubated (30 min at
37°C) with 5 nM [ 3H] phorbol 12,13-dibutyrate (0.03 Ci per tube;
DuPont NEN) with or without 10 M unlabeled phorbol dibutyrate to
define nonspecificity. Aliquots of the supernatant cytosolic fraction were
added to Tris BSA containing 1 mM CaCl2, 10 mM MgCl2, and 0.5 mg/ml
sonicated phosphatidylserine (Sigma) before equivalent incubation with
ligand. Bovine -globulin (to 0.6 mg/ml) and polyethylene glycol-8000 (to
20%) in 50 mM Tris HCl were added to cytosol samples and incubated
for 20 min at 4°C to precipitate proteins. After centrifugation at 12,000
g for 20 min, all samples were aspirated, and radioactivity in the pellets
was measured by liquid scintillation counting.
RESULTS
Behavioral reflex studies
Neuropathic animals showed behavioral alterations after CCI
that were consistent with previous data from our laboratory
(Blackburn-Munro and Fleetwood-Walker, 1999; Dickinson et
al., 1999). Development of neuropathic behaviors became mea-
surable at 8 d after surgery, with peak changes at 12–14 d. Most
experiments were performed using CCI animals taken at 12–14 d
after surgery, although some samples for time course studies were
taken at 4 and 8 d.
Sensory responses of single dorsal horn neurons:
application of inhibitors of the proteasome complex
Most of the recorded neurons were multi-receptive, responding to
both innocuous and noxious stimuli. They were estimated to be
located within dorsal horn laminas III–V at depths of 200–700
m from the surface of the spinal cord that were measured using
electrode contact at the dorsal surface and dye spot deposition in
histological sections after experimentation. To facilitate neuronal
classification and obtain sustained neuronal activation after mus-
tard oil application, only neurons with receptive fields on the
hairy skin of the hindlimb were investigated. Neuronal activation
to application of either innocuous brush or mustard oil stimuli to
the peripheral receptive field was found in the majority of re-
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corded neurons in both normal and neuropathic animals showing
peak behavioral reflex changes indicative of neuropathy. How-
ever, activation of neurons to cold stimuli (4°C) were found only
in neuropathic animals, which is in agreement with the observa-
tion that it is only neuropathic animals that develop a paw
withdrawal response to cold water (4°C). The spontaneous firing
rates of neurons were low (1–2 Hz), and those in response to the
stimuli were between 12 and 50 Hz. For each neuron, in the
majority of cases, the rate of firing in response to the different
stimuli, before drug application, was within 15 Hz. No significant
change in activity was ever observed during control ejection of
saline, pH 7.0, or the vehicle (0.5% aqueous dimethylformamide,
pH 4.5) at currents up to 60 nA for 5 min. In naive animals,
ionophoretic application of the proteasome inhibitors lactacystin
or MG-132 caused partial inhibition of mustard oil-induced ac-
tivity but no significant inhibition of brush-evoked activity (Fig.
1a,b; Table 1). The effects of lactacystin were similar in sham-
operated animals (Table 1).
In neuropathic animals, however, the drugs caused a greater
percentage reduction in all responses, inhibitory effects on brush
responses now becoming statistically significant (Fig. 1c–e; Table
1). The de novo responses to cold, which appeared only in neu-
ropathic animals, were also significantly inhibited by both lacta-
cystin and MG-132.
Figure 1. Typical effects of iono-
phoretic application of the proteasome
inhibitor lactacystin on stimulus-evoked
sensory responses of single dorsal horn
neurons in naive and neuropathic ani-
mals. In naive animals, lactacystin had
no effect on brush-evoked activation of
dorsal horn neuron cell firing rate, mea-
sured as action potentials per second
(A/s), but it caused a selective attenua-
tion of mustard oil-evoked activation of
dorsal horn neuron cell firing (a, b). In
contrast, in neuropathic animals, lacta-
cystin reduced dorsal horn neuron fir-
ing evoked by application of brush,
mustard oil, and cold stimuli to the neu-
ronal receptive field area (c–e). The bar
(bottom right) indicates 1 min duration.
Lines above the firing records indicate
the duration of the drug application by
ionophoresis, close to the recorded cell.
This is measured in nanoamperes (nA)
of current used to eject the drug and
was increased sequentially by 10 nA ev-
ery 1–2 min.
Table 1. Effects of ionophoretically applied proteasome inhibitors on sensory responses of single dorsal horn neurons
Drug Condition
% of stimulus-evoked response remaining
Brush Mustard oil Cold
Lactacystin 87.5 	 5.9 58.6 	 7.1*
Naive (n  8) (n  7)
(10 –60 nA) (10 –60 nA)
79.2 	 1.6 50.1 	 6.2*
Sham (n  3) (n  4)
(50 –60 nA) (10 –40 nA)
60.8 	 4.2* 34.1 	 5.1 58.7 	 4.7*
Neuropathic (n  4) (n  6) (n  3)
(20 –60 nA) (20 –40 nA) (10 –30 nA)
MG-132 76.4 	 2.5 57.1 	 8.8*
Naive (n  4) (n  4)
(10 –40 nA) (20 –40 nA)
66.4 	 5.4* 31.6 	 2.1* 48.3 	 7.4*
Neuropathic (n  4) (n  7) (n  3)
(30 –60 nA) (10 –30 nA) (10 –30 nA)
Data are expressed as mean 	 SEM (n values in parentheses). Using mean firing rates over 15 sec bins, the statistical significance of differences between maximally inhibited
firing rates in the presence of drug and firing rates immediately before ionophoresis were calculated by Kruskal–Wallis one-way ANOVA, followed by a post hoc Dunn’s test
(*p  0.05). The ranges of ionophoretic currents required to reach a maximal depression of firing rate are indicated. Further increases in currents beyond these values caused
greater inhibition.
1366 J. Neurosci., February 15, 2002, 22(4):1363–1372 Moss et al. • Proteasome Function in Neuropathic Pain
Behavioral reflex changes after intrathecal
administration of the proteasome inhibitors MG-132
and epoxomicin
Intrathecal administration of the proteasome inhibitors MG-132
(5 nmol/50 l) and epoxomicin (0.75 nmol/50 l) in rats exhib-
iting peak neuropathic behavioral changes significantly reversed
thermal hyperalgesia and mechanical and cold allodynia over a 90
min period (Fig. 2a–c). Control intrathecal administration of
vehicle in CCI rats had no significant effect on baselines (Fig.
2a–c). The intrathecal administration of proteasome inhibitors in
naive rats had no significant effect on baseline values (data not
shown).
mRNA analysis by RT-PCR
A semiquantitative RT-PCR approach was used for the screening
of the UCH-L1 gene, the expression of which may be altered in a
Figure 2. The effects of intrathecal administration of the proteasome inhibitors epoxomicin and MG-132 on reflex withdrawal responses to noxious
thermal, innocuous mechanical, and innocuous cold stimuli in CCI rats. Data are presented as the mean paw withdrawal latency (in seconds) to noxious
thermal stimulation (a, b), paw withdrawal threshold in milliNewtons per millimeters squared (mN/mm2) to mechanical stimulation (c, d), and suspended
paw elevation time in seconds [SPET(s)] to cold water (at 4°C) (e, f ), before and after intrathecal administration of epoxomicin (0.75 nmol/50 l) (a–c)
and MG-132 (5 nmol/50 l) (d–f ), respectively (at arrow). Injection of vehicle (0.5% dimethylformamide in saline) had no detectable effect on reflexes.
Paw withdrawal latency from noxious heat and innocuous cold stimuli ipsilateral to CCI showed significant differences between pre-drug and post-drug
administration values (†p  0.05; one-way ANOVA, followed by a Dunnett’s post hoc test). Significant differences between contralateral and ipsilateral
paw are indicated (*p  0.05; Student’s paired t test). Paw withdrawal thresholds to mechanical stimulation ipsilateral to CCI showed significant
differences between pre-drug and post-drug administration values (†p  0.05; Kruskal–Wallis one-way ANOVA, followed by a post hoc Dunn’s test).
Significant differences between contralateral and ipsilateral paw withdrawal thresholds are indicated (*p 0.05; Mann–Whitney U test).
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neuropathic state. Using the samples described previously,
changes in the abundance of PCR product were normalized
against GAPDH levels (Fig. 3a). GAPDH has previously been
shown to be a stable and consistent housekeeping standard in
cases of spinal cord and brain insult (Medhurst et al., 2000).
RT-PCR performed on cDNA extracted from the spinal cord of
rats using a PCR mixture containing primers to UCH-L1 and
GAPDH generated two distinct PCR products of 324 and 292 bp,
respectively (Fig. 3a). Analysis was performed on points in the
PCR process at which exponential amplification was observed
(whereby the abundance of both UCH and GAPDH is directly
proportional to the level of respective mRNA in the sample).
Concurrent PCR on samples for which reverse transcriptase was
omitted produced no detectable amplification products (data not
shown). A statistically significant increase (mean  47%) in the
relative abundance of UCH-L1 mRNA was seen in the ipsilateral
as compared with the contralateral spinal cord hemisection at 14 d
(Fig. 3a). No significant changes in mRNA levels were observed
between spinal cord sections of sham-operated or naive rats or
ipsilateral to CCI in animals taken 4–8 d after nerve ligation.
In situ hybridization histochemistry
In accordance with the expression of UCH-L1 protein throughout
eukaryotic neural and neuroendocrine cell types and in line with
its role in proteasomal functioning, the mRNA for rat UCH-L1
was distributed widely in spinal cord of both naive and neuro-
pathic animals. After CCI, there were distinct changes in the
expression of mRNA for UCH-L1 in the dorsal horn ipsilateral to
nerve injury, compared with contralateral and naive values. The
total number of neurons positively expressing mRNA for
UCH-L1 was significantly increased in the ipsilateral dorsal horn,
both medially in laminas I, II, and III and laterally in laminas I
and II (Fig. 3b; Table 2). Silver grain density was significantly
increased mediolaterally in laminas I, II, III, and V and laterally
in laminas I, II, and III (Fig. 3b; Table 2). The significant incre-
ments in numbers of hybridizing cells and silver grain density
ranged from 22–28 to 17–41%, respectively. Within the ventral
horn of normal animals, labeling of motoneurons was especially
intense but showed no significant change after CCI treatment
(data not shown).
Western blot analysis to monitor changes in protein
levels of UCH-L1 after CCI
To determine whether the increase in UCH-L1 mRNA after CCI
leads to an overall increase in the translation of its protein
product, we performed Western blot analysis using an antibody
specific to UCH-L1. Densitometry of immunoreactive bands re-
vealed an ipsilateral increase of 27–31% after CCI when compared
with contralateral, sham-operated, and naive sample values. Sam-
ples were normalized in relation to levels of the established cellular
housekeeper enzyme GAPDH, and values were expressed as the
percentage relative GAPDH expression (Fig. 4a,b).
Regulation of constitutive spinal cord PKA activity by
the ubiquitin–proteasome system
To obtain a readout of the function of the ubiquitin–proteasome
system in spinal cord, we monitored the enzymatic activity of
PKA, the activity of which is known to be regulated through
Figure 3. Determination of levels of
mRNA for ubiquitin C-terminal
hydrolase-L1 (UCH-L1). a, Relative
abundance of UCH-L1 mRNA from
spinal cord of CCI-treated rats as as-
sessed by semiquantitative RT-PCR
normalized to the signal obtained for
the cellular housekeeping enzyme
GAPDH. Densitometric analysis indi-
cated that the relative UCH-L1 expres-
sion was similar in all conditions except
in tissue ipsilateral to CCI at 14 d,
where expression was significantly
greater than that in contralateral sam-
ples (*p  0.05 by paired Student’s t
test; n  3). Further analysis of the
changes at 14 d after CCI was made by
in situ methods. See b and Table 2 for
quantification data. b, In situ hybridiza-
tion histochemistry to show UCH-L1
mRNA expression in lamina I of the rat
medial dorsal horn. High-power, light-
field photomicrographs showing that
expression of mRNA for UCH-L1 was
higher ipsilateral to CCI after 14 d,
compared with contralateral tissue and
naive dorsal horn. Scale bar, 100 m.
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degradation of the regulatory subunits by the proteasome (Hegde
et al., 1997; Chain et al., 1999). Degradation of regulatory sub-
units, leaving a relative excess of unrestrained catalytic subunits,
is thought to lead to an elevated level of constitutive enzyme
activity, which can be monitored by ex vivo enzyme assays (Ros-
koski, 1983). Table 3 shows that the fraction of PKA activity that
was constitutive was significantly elevated in spinal cord ipsilat-
eral to CCI and that this elevation was prevented by local admin-
istration of the selective proteasome inhibitors epoxomicin and
MG-132 to the spinal cord. This matches our other molecular and
physiological data in suggesting that the activity of the ubiquitin–
proteasome system is elevated in response to nerve injury.
Effects of proteasome inhibitor on CCI-induced
translocation of [3H] phorbol dibutyrate binding sites
To investigate whether CCI-induced activation of PKC is altered
by inhibition of the proteasome, we measured cytosol /membrane
translocation of specific [3H] phorbol dibutyrate binding sites
after topical administration of the proteasome inhibitor epoxomi-
cin. In accordance with previous reports (Mao et al., 1993a,b), we
found clear increases in specific binding of [3H] phorbol dibu-
tyrate to the membrane rather than cytosolic fraction of tissue
ipsilateral to CCI (Table 4). Smaller but still statistically signifi-
cant increases were seen also on the contralateral side. Intrathecal
administration of epoxomicin caused no detectable alteration in
the translocation of [3H] phorbol dibutyrate binding sites (either
Table 2. In situ hybridization histochemistry for UCH-L1 mRNA expression after CCI
Laminas
Mediolateral Lateral
CCI/ipsilateral CCI/contralateral Naive CCI/ipsilateral CCI/contralateral Naive
Mean number of hybridizing cells per section in spinal dorsal horn
LI 35.5 	 1.2* 26.6	 0.5 25.9 	 1.1 32.2 	 1.4* 24.4	 1.1 22.5 	 2.5
LII 35.2 	 1.8* 25.5	 1.2 25.5 	 1.4 34.2 	 1.8* 28.2	 2.1 30.1 	 1.3
LIII 37.1 	 1.9* 30.5	 1.2 30.5 	 1.5 36.5 	 3.1 32.5	 2.5 35.6 	 2.2
LIV 42.2 	 2.2 38.2	 3.2 38.8 	 3.4 41.1 	 2.1 40.5	 1.4 40.1 	 1.3
LV 38.9 	 1.4 36.5	 1.8 37.5 	 2.2 32.5 	 1.2 32.1	 0.6 32.4 	 1.0
Mean number of silver grains per cell
LI 14.5 	 1.3* 10.3	 0.8 8.8 	 1.3 12.4 	 1.3* 9.2	 1.2 8.8 	 0.4
LII 14.5 	 1.2* 11.6	 0.8 11.1 	 1.2 13.6 	 1.2* 10.3	 0.9 10.0 	 0.6
LIII 29.8 	 2.3* 21.5	 1.6 19.2 	 2.3 29.5 	 2.5* 24.8	 2.1 24.8 	 1.9
LIV 39.4 	 2.2 35.1	 2.1 34.9 	 2.2 35.8 	 2.2 33.8	 1.8 32.0 	 1.9
LV 40.0 	 1.8* 31.0	 2.1 32.0 	 1.8 39.2 	 3.1* 33.4	 2.1 32.0 	 2.0
Data show both the mean number of cells expressing UCH-L1 mRNA and the mean density of silver grains. Ipsilateral values were compared with both the contralateral side
in CCI animals taken at peak behavioral change and with naive, unoperated values (*p  0.05; one-way ANOVA, followed by a Dunnett’s post hoc test). For all laminas
analyzed, there was no significant alteration in the relative expression of UCH-L1 mRNA when comparing contralateral CCI values with naive values.
Figure 4. Western blot analysis of the expression of UCH-L1 protein.
Western blots of spinal cord samples from neuropathic, naive, and sham-
operated rats. a shows an increase in UCH-L1 protein expression ipsilat-
eral (Ipsi) to CCI in neuropathic animals. No change from naive samples
was observed in the sham-operated or contralateral side (Contra) of CCI
samples. b represents UCH-L1 expression as a percentage of GAPDH
expression in terms of relative gray scale values after quantitative densi-
tometry of ECL films. Data are presented as mean 	 SEM (n  3; *p 
0.05, from control contralateral values; Student’s paired t test).
Table 3. Effects of the topical administration of the proteasome
inhibitors epoxomicin and MG-132 on constitutive activation of protein
kinase A induced by CCI
Topical administration
PKA activity of spinal cord homogenates




Nil 9.5 	 1.0 15.7 	 1.2* 8.5 	 0.5
Vehicle 7.9 	 0.8 14.4 	 1.5* 9.1 	 0.5
Epoxomicin 8.4 	 1.0 9.9 	 0.8† 8.1 	 1.1
MG-132 — 7.8 	 0.2† 8.6 	 0.5
After topical administration under anesthesia of 500 l of epoxomicin (15 M),
MG-132 (100 M), or vehicle (0.5% dimethylformamide in saline), spinal segments
(L3–L6) were removed and hemisected, before homogenization in cold buffer.
Samples were assayed for authentic PKA [33P] phosphotransferase activity under
constitutive and maximal cAMP-evoked conditions. Total authentic PKA activity
was in the order of 100–200 pmol  min1  mg1 tissue under these conditions and
similar between ipsilateral and contralateral CCI tissue. Values are expressed as
means 	 SEM (n  6–8). * indicates significantly greater than corresponding
contralateral CCI values and naive control values (p  0.05), by Wilcoxon test and
Mann–Whitney U test, respectively. † indicates significantly less than corresponding
vehicle-treated tissue ipsilateral to CCI (p  0.05 by Mann–Whitney U test).
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ipsilateral or contralateral to CCI) under conditions in which it
was shown to reduce the ipsilateral increase in constitutive activ-
ity of PKA (Tables 3, 4).
DISCUSSION
Injury in afferent nerves can elicit their sustained firing and result
in phenotypic and functional changes both within dorsal root
ganglia and in the dorsal horn of the spinal cord. The resulting
state of central sensitization plays a key role in bringing about the
hyperalgesia and allodynia, as well as sensitivity to cold, that
characterize neuropathic pain states. We now provide evidence to
suggest that the ubiquitin–proteasome system is important in the
cellular mechanisms underlying neuropathic sensitization after
CCI. The proteasome also appears to play a role in the normal
spinal processing of noxious, but not innocuous, sensory stimuli.
After CCI, previously innocuous stimuli such as brush and cold
are perceived as noxious and correspondingly show sensitivity to
blockade by proteasome inhibitors. Both the behavioral reflex
studies and especially the electrophysiological experiments in
animals with established CCI sensitization showed a rapid onset
of activation of the proteasome inhibitors. Several structurally
distinct proteasome inhibitors exhibited similar effects, suggesting
that they are effective because of their actions on the proteasome.
The rapidity of action suggests that ongoing degradation of a key
signaling regulator (such as PKA regulatory subunits) is actively
essential for the maintenance of established neuropathic sensiti-
zation. The contribution of the ubiquitin–proteasome system to
sensitization was closely paralleled by increased expression (ipsi-
lateral to nerve injury) of UCH-L1 at the level of RT-PCR, in situ
hybridization (ISHH), and immunoblot. The steady-state eleva-
tion of UCH-L1 expression observed here at 14 d after CCI is less
than the acute rise seen within 4 hr after LTF in Aplysia (Hegde
et al., 1997). This may relate in part to the higher basal levels of
UCH-L1 in mammalian neurons (Wilkinson et al., 1989). Fur-
thermore, the CCI sensitization model differs from LTF in that
changes in spinal neuronal function develop slowly and are then
maintained over many days. If optimal UCH-L1 activity is re-
quired for operation of the ubiquitin–proteasome system and this
pathway plays a greater functional role after CCI (as demon-
strated) then even small changes in UCH-L1 such as the incre-
ment of 30% seen in RT-PCR, ISHH, and immunoblot meth-
ods may be functionally significant. We do not know whether the
level of UCH-L1 expression is rate limiting for proteasome func-
tion here, but if that is the case (as appears to be so in Aplysia
LTF), then the requirement for ongoing proteasome activity
shown by the inhibitor results suggests that small increases might
well result in functional change. The time course of the increase
in UCH-L1 mRNA ipsilateral to CCI matched closely the devel-
opment of behavioral reflex sensitization that we observed, being
clearly established by 14 d after nerve ligation. No significant
increases were detected at 4 or 8 d after surgery, times at which
thermal hyperalgesia, mechanical allodynia, and cold allodynia
were undetectable and showed 25% development of maximal
effect, respectively, in these experiments. UCH-L1 plays an es-
sential role in the recycling of ubiquitin, which is necessary to
maintain adequate rates of proteasome-mediated degradation of
proteins. The regulatory subunits of PKA are an example of such
a known proteasome target, and their degradation is thought to
lead to the formation of constitutively active PKA. In accordance
with our other data, elevated levels of constitutively active PKA
were found in spinal cord ipsilateral to CCI, and this increase was
reversed by acute local administration of a selective proteasome
inhibitor. No changes were observed in the CCI-induced cytosol
to membrane translocation of PKC, an alternative signal trans-
duction mediator, which is not considered to be directly influ-
enced by proteasome function.
Activity-dependent synaptic changes, associated with altered
states of responsiveness and “synaptic memory,” have been in-
vestigated in LTF in Aplysia (Bailey and Kandel, 1993) and in
LTP in central mammalian neurons (Bliss and Collingridge,
1993). Although the precise nature and origin of these alterations
differ, they may share a number of common features with the
central sensitization that occurs within the spinal cord in response
to chronic activation of nociceptive inputs.
Neuropathic sensitization is similar to other forms of repetitive
input-induced sensitization in spinal cord (such as wind-up and
inflammatory sensitization) in its dependence on NMDA recep-
tor function (Mao et al., 1993a,b; Tal and Bennett, 1993). Al-
though distinct neurochemical changes in these different pain
states suggest that the mechanisms leading to NMDA receptor
activation may differ, the NMDA receptor appears to be crucial
to the sensitization phenomenon. It is not yet clear whether all
forms of spinal sensitization rely on proteasome function as
neuropathic sensitization does. However, the attenuation by pro-
teasome inhibitors of both sub-acute mustard oil-evoked re-
sponses and neuropathic sensitization (which have in common a
dependence on NMDA receptor-mediated events) (Heppenstall
and Fleetwood-Walker, 1997) suggests that the role of the pro-
teasome may relate closely to NMDA receptor activation.
Whether the proteasome plays a role in processes leading to
NMDA receptor activation or in events downstream of either the
Ca2 entry-mediated or adapter protein-mediated signaling of
the receptor is not yet clear. Nevertheless, the proteasome clearly
represents an interesting new target in neuropathic and other
forms of pain.
PKA is implicated in spinal sensitization and pain (Cerne et
al., 1993; Sluka, 1997). PKA may be activated downstream of
receptors that lead to cAMP production (or downstream of
Ca2-mobilizing receptors, if Ca2-activated isoforms of adenyl-
ate cyclase are present) and among many other targets is known
to phosphorylate and activate both NMDA- and AMPA-type
glutamate receptors (Greengard et al., 1991; Roche et al., 1996;
Westphal et al., 1999). Although mutant mice with a targeted
deletion of one of the PKA regulatory subunits did not show any
attenuation of neuropathic sensitization (Malmberg et al., 1997),
the fact that PKA catalytic activity is normally restrained by the
Table 4. Lack of effect of topical administration of the proteasome








Vehicle 24.0 	 3.7 61.4 	 6.5* 46.0 	 4.9*
Epoxomicin 26.2	 2.9 61.0 	 4.8* 48.5 	 6.1*
After topical administration of epoxomicin or vehicle under anesthesia (as in Table
3), spinal cord segments L3–L6 were removed and hemisected before homogeniza-
tion in ice-cold buffer. Samples were assayed for membrane-bound and cytosolic
specific [3H]PDBu binding sites. Total recovered specific binding was in the order of
6000 dpm per sample aliquot and was similar in all conditions tested. Values are
means 	 SEM (n  5). * indicates significantly greater than naive control values
(p  0.05 by Mann–Whitney U test). PDBu, Phorbal dibutyrate.
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presence of regulatory subunits makes this difficult to interpret. In
the LTF model in Aplysia, PKA appears to play a key role in
increased responsiveness, and substantial evidence indicates that
an imbalance of PKA regulatory and catalytic subunits, mediated
by proteasome degradation of the former, is a crucial factor
(Hegde et al., 1993; Chain et al., 1999). This matches closely the
proteasome-dependent generation of constitutively active PKA
that we observed ipsilateral to CCI (Table 3). In the Aplysia
model, expression of the homolog of UCH-L1 is rapidly increased
in the facilitation paradigm (Hegde et al., 1997), again closely
paralleling the observations here with neuropathic sensitization,
except that the full development of the sensitized state here
occurs over a more prolonged time period. An alternative path-
way that is known to be subject to proteasome regulation is that
of the transcription factor, nuclear factor B (NF-B). NF-B
exists in a latent form in unstimulated cells, complexed to the
inhibitory protein, I-B. Inflammation-associated molecules, such
as cytokines, can induce I-B phosphorylation, leading to its
ubiquitination and degradation by the proteasome (Karin and
Delhase, 2000). Dissociated NF-B can then regulate the expres-
sion of various target genes, including the inducible enzymes
cyclo-oxygenase-2 and nitric oxide synthase, adhesion molecules,
cytokines, and neuropeptides (O’Neill and Kaltschmidt, 1997).
Although NF-B expression decreases acutely after nerve injury
(Doyle and Hunt, 1997), NF-B immunoreactivity has been re-
ported to increase within ipsilateral DRG neurons 2 weeks after
nerve injury (Ma and Bisby, 1998), perhaps in response to cyto-
kines and trophic factors secreted by non-neuronal cells during
Wallerian degeneration. In cerebellar granule neurons, NF-B
expression appears to be regulated by glutamate acting via
NMDA receptors (Guerrini et al., 1995). In pilot experiments
with intrathecal administration of the selective NF-B inhibitor
parthenolide (Alexis) to CCI rats (1.5 nmol/50 l 0.3% dimeth-
ylformamide in saline), we found no detectable change in behav-
ioral responses to heat, cold, or mechanical stimuli (data not
shown). This suggests that although certain proteasome targets
like PKA may play an important role in neuropathic sensitization,
others like the NF-B/I-B complex may not be important. Nev-
ertheless, more extensive studies on these and other pathways will
be necessary before it is clear how the proteasome plays out its
key role in enabling neuropathic sensitization.
In conclusion, we have unexpectedly shown that proteasome
inhibitors can selectively inhibit neuropathic sensitization, which
is likely to underlie the development of chronic intractable pain
after nerve injury. Importantly, proteasome inhibitors attenuate
neuropathic allodynia without impairing normal sensory re-
sponses to low-intensity peripheral stimuli, a particularly advan-
tageous therapeutic profile. Expression of a key enzyme in ubiq-
uitin–proteasome function is increased in spinal dorsal horn
ipsilateral to injury, as is the activity of a known target of the
complex (PKA), which is expected to display deregulated consti-
tutive activity after proteasome action. Proteasome-dependent
activation of PKA in neuropathic sensitization closely parallels
that in LTF in Aplysia. Proteasome inhibitors are under phase I
trials as anti-cancer drugs (Lee and Goldberg, 1998). In many
cases, advanced development of tumors leads to local inflamma-
tion and pressure trauma to afferent nerves, resulting in a neu-
ropathic component to cancer pain. The present study predicts
that in addition to any direct effect on cancer cells, proteasome
inhibitors would exert a useful additional role in attenuating the
central sensitization that leads to chronic hyperalgesia and
allodynia.
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